1 Result: Mesoblast
Mesoblast Faces Regulatory Setback; Nikola's Earnings: A Preview
August 04th, 2023
Mesoblast Limited (Nasdaq: MESO) has announced the receipt of a comprehensive response from the US Food and Drug Administration (FDA) regarding its Biologics License Application (BLA) resubmission for remestemcel-L. The FDA's response stipulates the . Read more
Load More Content
Want To Find Some News?
News By Industries
Recent Post
-
NJCP Football League Provides Development and Opportunity for Athletes Pursuing the Next Level
March 20th, 2026March 19th, 2026How High School Graduates Can Kickstart Their Football Career
March 18th, 2026
Member Login